ライフサイエンスコーパス: therapeutic drug

1 pathway and a potentially clinically useful therapeutic drug.

2 alyses for the characterization of a protein therapeutic drug.

3 There is no licensed vaccine or therapeutic drug.

4 le model for the testing of novel classes of therapeutic drug.

5 RA is also a therapeutic drug.

6 and SIRT1 has precluded the use of RSV as a therapeutic drug.

7 to understand tumorigenesis and develop new therapeutic drugs.

8 ation and therefore impact their efficacy as therapeutic drugs.

9 targets to modulation by potent and specific therapeutic drugs.

10 chemical toxins and carcinogens, and >80% of therapeutic drugs.

11 portant targets for the development of novel therapeutic drugs.

12 lism, efficacy, and side effects of numerous therapeutic drugs.

13 east in part, attributable to the effects of therapeutic drugs.

14 represent viable targets for development of therapeutic drugs.

15 ection, but also reduced penetration of many therapeutic drugs.

16 -production, without loading of any specific therapeutic drugs.

17 of mechanosensitive channels of pathogens by therapeutic drugs.

18 was used for the detection of two carbamate therapeutic drugs.

19 rgeted during the search for prophylactic or therapeutic drugs.

20 processes, making them important targets for therapeutic drugs.

21 for development of safe and effective cancer therapeutic drugs.

22 nals and are targets for a large fraction of therapeutic drugs.

23 an enzyme involved in the metabolism of many therapeutic drugs.

24 nesterase (AChE) is a significant target for therapeutic drugs.

25 s has a significant impact on the actions of therapeutic drugs.

26 sed for enhancing intra-NP residence time of therapeutic drugs.

27 serve as a basis for the development of new therapeutic drugs.

28 oviding a new framework for developing novel therapeutic drugs.

29 determinants with other SCI insecticides and therapeutic drugs.

30 receptors and are the most common target of therapeutic drugs.

31 onitor improved glycosylation in response to therapeutic drugs.

32 nd measure single cell responses, such as to therapeutic drugs.

33 in the clearance and detoxification of many therapeutic drugs.

34 gy of disease, and the responses of cells to therapeutic drugs.

35 t in neural cells and a potential target for therapeutic drugs.

36 thus reduce brain accumulation of CNS-acting therapeutic drugs.

37 innovative approaches to the development of therapeutic drugs.

38 TBI as well as a useful screening method for therapeutic drugs.

39 i and are the molecular targets for numerous therapeutic drugs.

40 linical applications of immunophilin-related therapeutic drugs.

41 become a novel target for the development of therapeutic drugs.

42 cesses in response to endogenous ligands and therapeutic drugs.

43 ery platform in developing galectin-targeted therapeutic drugs.

44 re targets of disease mutations, toxins, and therapeutic drugs.

45 m, transcriptional regulation and developing therapeutic drugs.

46 tually for designing new molecules toward AD therapeutic drugs.

47 ab-paclitaxel and other albumin-based cancer therapeutic drugs.

48 some(R) an efficient carrier for delivery of therapeutic drugs across the skin barrier.

49 logical roles in neural circuit function and therapeutic drug actions.

50 atural compound could be used as a potential therapeutic drug against KSHV malignancies involving vGP

51 mportant target for the development of novel therapeutic drugs against human diseases.

52 equire new practices including more frequent therapeutic drug and clinical monitoring, and increased

53 ein inhibitors, molecular detection systems, therapeutic drugs and antibody replacement among others.

54 ease measurement, and the development of new therapeutic drugs and approaches are needed to improve o

55 s may provide novel opportunities to develop therapeutic drugs and chemical tools.

56 stigated and considered for oral delivery of therapeutic drugs and diagnostic materials.

57 xicities but also may reveal new targets for therapeutic drugs and diagnostic tools.

58 s of the gut microbiome on the metabolism of therapeutic drugs and diet-derived bioactive compounds.

59 ic cytochromes P450 (CYP450s) in response to therapeutic drugs and environmental contaminants, leadin

60 Therapeutic drugs and environmental pollutants may exhib

61 chloride co-transporters that are targets of therapeutic drugs and mutated in several human diseases.

62 n tumor bulk, leading to reduced efficacy of therapeutic drugs and radiotherapy.

63 has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contra

64 derlying neurobiology of ASD and identifying therapeutic drugs and/or drug targets.

65 he GPP subpocket, as compared to the current therapeutic drugs, and rigidify the (364)KRRK(367) tail

66 Monitoring the concentration of a therapeutic drug antibody, infliximab (IFX), is recommen

67 Consequently, therapeutic drugs are designed to target GPCRs at the pl

68 rging resistance to current medications, new therapeutic drugs are needed.

69 major therapeutic importance, and potential therapeutic drugs are screened against SIRT1 deacetylase

70 d chain to revolutionize the way many labile therapeutic drugs are stored and utilized throughout the

71 afosfamide and fludarabine showed that these therapeutic drugs are synergistic in B-CLL whole blood a

72 They show that the therapeutic drug arsenic trioxide (AS(2)O(3)) targets BC

73 Monitoring of trace-levels of chemicals in therapeutic drugs, as well as in food safety and environ

74 They also prevent the entry of therapeutic drugs at the BBB, thereby limiting their eff

75 of other analytes including theophylline, a therapeutic drug, at a concentration as low as 1.0 x 10(

76 dies (mAbs) are the fastest growing class of therapeutic drugs, because of their high specificities t

77 al advances in stroke research, with several therapeutic drugs being able to enhance clinical outcome

78 fully demonstrated by the N-oxidation of two therapeutic drugs, benzydamine (nonsteroidal anti-inflam

79 anning electron microscopy revealed that the therapeutic drug candidate beta-cyclodextrin induces the

80 luated further as a potential preventive and therapeutic drug candidate for AD.

81 rylation and suggest that LY5 is a promising therapeutic drug candidate for medulloblastoma by inhibi

82 K using the approved drug denosumab may be a therapeutic drug candidate for primary lung cancer.

83 drug discovery programmes, as many potential therapeutic drug candidates have poor BBB permeation.

84 toxicity induced by the frontline anticancer therapeutic drug cisplatin, which has been associated wi

85 The cancer-therapeutic drug, cisplatin, induces the release of GDF1

86 tential medication overuse risk of two novel therapeutic drug classes, namely the ditans: 5-HT1F rece

87 d toward effective point-of-care devices for therapeutic drug concentration monitoring.

88 e exact tumor site as well as an appropriate therapeutic drug concentration with a controlled release

89 By contrast, sustained therapeutic drug concentrations in aqueous humor can be

90 long-acting (LA) antiretrovirals can sustain therapeutic drug concentrations in blood for prolonged t

91 hat the delivery of high doses could achieve therapeutic drug concentrations in the brain and cerebro

92 xperimental therapeutics, aimed at achieving therapeutic drug concentrations in the brain, with assoc

93 possible, evidence to confirm the safety and therapeutic drug concentrations of a nevirapine-based an

94 (BBB), and so are shielded from exposure to therapeutic drug concentrations.

95 ne is able to reverse GC resistance, even at therapeutic drug concentrations.

96 a low concentration of bupropion that mimics therapeutic drug conditions inhibits 5-HT-induced curren

97 Resistance of leishmanial parasites to therapeutic drugs continues to escalate in developing co

98 While the application of EVs for therapeutic drug delivery is still in its infancy, issue

99 Harnessing exosomes as therapeutic drug delivery vehicles requires a better und

100 neural stimulation, neural regeneration, and therapeutic drug delivery.

101 cellular drug resistance and interferes with therapeutic drug delivery.

102 liability, which may be exploited in future therapeutic drug design for cocaine use disorder.

103 signaling may also have implications for the therapeutic drug design.

104 aspase-6 has been identified as a target for therapeutic drug development for the treatment of this d

105 n and contribute to both delays and costs of therapeutic drug development.

106 atory site that also represents a target for therapeutic drug development.

107 stable foldon and suggest new strategies for therapeutic drug development.

108 l is a major goal of fundamental biology and therapeutic drug development.

109 itizing potentially targetable gene sets for therapeutic drug development.

110 t step towards lead compound development for therapeutic drug development.

111 t with this, accumulation of fumarate by the therapeutic drug dimethyl fumarate (DMF) also promotes U

112 Therefore, local intra-discal injection of therapeutic drugs directly into the NP is a clinically r

113 Significant investments in therapeutic drug discovery programs over the past two de

114 de bladder cancer to serve as a platform for therapeutic drug discovery.

115 hways is emerging as a powerful approach for therapeutic drug discovery.

116 ess of protein kinase inhibitors as approved therapeutics, drug discovery has focused on a small subs

117 This strategy allows for a reduction in the therapeutic drug dose, which may reduce harmful side eff

118 he respiratory drive at 0.1% of the systemic therapeutic drug dose.

119 of schizophrenia and to monitor potentially therapeutic drug effects for both treatment and preventi

120 Therapeutic drug efficacy and tolerability of memantine

121 are important human enzymes that metabolize therapeutic drugs, environmental chemicals, and physiolo

122 he method's ability to show how and when the therapeutic drug exerts protective and/or healing effect

123 he disease, it remains a target for which no therapeutic drug exists.

124 ine (CQ) has been used as first line malaria therapeutic drug for decades.

125 ion; therefore, it could possibly be a novel therapeutic drug for fibrosis.

126 piprazole represents a potentially promising therapeutic drug for Machado-Joseph disease and possibly

127 f stroke and has passed clinical trials as a therapeutic drug for stroke in China.

128 o study the metabolism of DOPA, a well-known therapeutic drug for treating Parkinson's disease.

129 P2Y(1)R agonists could potentially act as a therapeutic drug for treating prostate cancer.

130 form of arsenic trioxide (ATO) is used as a therapeutic drug for treatment of acute promyelocytic le

131 al cancer effects of metformin, a first-line therapeutic drug for type 2 diabetes mellitus, and nelfi

132 Cisplatin is one of the most commonly used therapeutic drugs for cancer therapy, yet prolonged cisp

133 proved small molecules to identify candidate therapeutic drugs for COVID-19.

134 2) over a 12-week period in the Genome-Based Therapeutic Drugs for Depression (GENDEP) project, a par

135 he hypothesis was tested in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study, a multi

136 de pharmacogenetic studies (the Genome-Based Therapeutic Drugs for Depression [GENDEP] project, the M

137 3) a pharmacogenetic study (the Genome-Based Therapeutic Drugs for Depression [GENDEP] study; N=88).

138 elopment will accelerate the delivery of new therapeutic drugs for front-line therapy for those child

139 hat are currently underway to find effective therapeutic drugs for KRAS mutant lung cancer.

140 ntially lethal but also have applications as therapeutic drugs for neurodegenerative diseases such as

141 the impact of selected ferrociphenols as new therapeutic drugs for such cancers.

142 onal antibodies are most rapidly emerging as therapeutic drugs for the treatment of cancer and of var

143 ses could greatly help in the development of therapeutic drugs for the treatment of these pathologies

144 to lead to the development of a new class of therapeutic drugs for treating LCA.

145 rgeted small molecules have shown promise as therapeutic drugs for treating RA.

146 at selective TRPV1 antagonists are potential therapeutic drugs for treating retinoid-induced sensory

147 We identified 27 cancer therapeutic drugs for which TP53 mutations conferred res

148 The therapeutic drugs gabapentin and pregabalin (PGB), which

149 l resistance to currently approved influenza therapeutic drugs has developed.

150 ditions, the encapsulated imaging agents and therapeutic drugs have been successfully delivered to ta

151 vivo biosensors and the DDSs for delivery of therapeutic drugs holds an enormous potential in next-ge

152 inflammatory properties has been tested as a therapeutic drug in clinical trials of China.

153 cancer cell resistance, low accumulation of therapeutic drug in the lungs, and severe adverse treatm

154 ligands, which are of increasing interest as therapeutic drugs in all the superfamily.

155 g and quantitating controlled substances and therapeutic drugs in biofluids typically require laborio

156 red in an attempt to improve the analysis of therapeutic drugs in dried blood spots (DBS).

157 r the intrinsic clearance of the majority of therapeutic drugs in humans.

158 a promising strategy for the design of novel therapeutic drugs in Parkinson's disease.

159 nt creates a physiological barrier for using therapeutic drugs in the stomach.

160 es as targeting motifs, and the inclusion of therapeutic drugs in their composition, is certain to ma

161 s below 10%, have been obtained for selected therapeutic drugs in whole blood throughout their indivi

162 s into how the BTB can be modulated to allow therapeutic drugs, including male contraceptives, to be

163 CRs are the target of more than one third of therapeutic drugs, including many drugs used to treat di

164 In this study, we tested the hypothesis that therapeutic drugs inhibit the intestinal thiamine transp

165 te targeting ligands, imaging agents, and/or therapeutic drugs into particles as an integral part of

166 Effective delivery of therapeutic drugs into the human brain is one of the mos

167 f disease management and a disease-modifying therapeutic drug is now available for patients with high

168 results provide proof of concept for BKIs as therapeutic drug leads in an animal model for human cryp

169 he use of de novo sirolimus requires careful therapeutic drug level monitoring, especially the first

170 been used in the clinic to provide sustained therapeutic drug levels at a target site, and thereby re

171 lectivity specifically to the heart, wherein therapeutic drug levels can be maintained over time, is

172 CEP-1347-treated mice readily achieve therapeutic drug levels in peripheral blood.

173 resection cavity, while systemic delivery of therapeutic drug levels to the brain tumour is limited b

174 ough a single infant was reported to develop therapeutic drug levels.

175 (8%), despite rapid viremia suppression and therapeutic drug levels; for 10 months, this virus remai

176 acks from chronic viral infection, uptake of therapeutic drugs, life behavior (alcoholic), and enviro

177 tion of proteins and other molecules such as therapeutic drugs, limiting its broader use.

178 Therapeutic drug monitoring (TDM) aid therapeutic decisi

179 greatly facilitates using the DBS method for therapeutic drug monitoring (TDM) for improving the effi

180 along with various techniques available for therapeutic drug monitoring (TDM) in cancer patients tre

181 h a narrow therapeutic dosage range to which therapeutic drug monitoring (TDM) is applied.

182 In such a trend, therapeutic drug monitoring (TDM) is especially crucial

183 Routine therapeutic drug monitoring (TDM) is necessary to facili

184 Therapeutic drug monitoring (TDM) of antiepileptic drugs

185 ssue of Blood, Tong et al have reported that therapeutic drug monitoring (TDM) of asparaginase (ASP)

186 Therapeutic drug monitoring (TDM) provides valuable guid

187 are market analytical platforms that perform therapeutic drug monitoring (TDM) without relying on mAb

188 Therapeutic drug monitoring (TDM), which involves measur

189 man spectroscopy as point-of-care method for therapeutic drug monitoring (TDM).

190 pecificity, making it an ideal candidate for therapeutic drug monitoring (TDM).

191 used in clinical chemistry laboratories for therapeutic drug monitoring (TDM).

192 mphoblastic leukemia are individualized with therapeutic drug monitoring (TDM).

193 Antimicrobial synergy testing and therapeutic drug monitoring allowed for assessment of tr

194 anagement strategy that incorporates routine therapeutic drug monitoring and dose adjustment over cur

195 ce pharmacokinetic variability by the use of therapeutic drug monitoring and include measurement of t

196 gnized, with multiple applications in, e.g., therapeutic drug monitoring and toxicology.

197 virologically suppressed, in settings where therapeutic drug monitoring and/or close viral load moni

198 s, but optimal dosing and appropriate use of therapeutic drug monitoring are not yet fully understood

199 Antimicrobial synergy testing and therapeutic drug monitoring assessed treatment adequacy.

200 h the use of dosing software supplemented by therapeutic drug monitoring data should be embedded into

201 Therapeutic drug monitoring did not reveal any clinicall

202 applications of wearable chemical sensors is therapeutic drug monitoring for drugs that have a narrow

203 Therapeutic drug monitoring has been added to our ALL-11

204 determine the real-world clinical utility of therapeutic drug monitoring in psoriasis.

205 e aimed to determine whether dosing based on therapeutic drug monitoring increases rate of remission

206 te exposure of fluconazole improves outcome, therapeutic drug monitoring is currently not recommended

207 Therapeutic drug monitoring is seen as a valuable tool t

208 Therapeutic drug monitoring may be a useful method to pr

209 Therapeutic drug monitoring may be advantageous when the

210 Therapeutic drug monitoring of fluconazole can be a valu

211 veloped method offers a new strategy for the therapeutic drug monitoring of NOACs and may improve the

212 the appropriateness of 125 as target ratio, therapeutic drug monitoring or dose adjustments might be

213 drug to the right patient at the right dose, therapeutic drug monitoring solutions are necessary.

214 oncentrations of first-line drugs were below therapeutic drug monitoring targets.

215 Therefore, it is highly recommended for therapeutic drug monitoring to control the drug level.

216 n the denaturating solution used in standard therapeutic drug monitoring to detach the drug from the

217 Intravenous busulfan combined with therapeutic drug monitoring to guide dosing improves out

218 tate timely selection of antimicrobials, and therapeutic drug monitoring would provide a more individ

219 y), and to personalize and optimize therapy (therapeutic drug monitoring).

220 l, (7) document antibiotic plan, (8) perform therapeutic drug monitoring, and (9) discontinue antibio

221 should incorporate rapid fungal diagnostics, therapeutic drug monitoring, and clinical intervention t

222 tion, interventions to optimize utilization, therapeutic drug monitoring, and data analysis and repor

223 ation for bioanalytical applications such as therapeutic drug monitoring, doping in sports, and pharm

224 care, personal diagnosis or for personalized therapeutic drug monitoring.

225 ping in sports, in vivo tissue sampling, and therapeutic drug monitoring.

226 rgeted drug delivery, molecular imaging, and therapeutic drug monitoring.

227 s recently emerged as an innovative tool for therapeutic-drug monitoring (TDM), making it an ideal ca

228 the development and clinical use of several therapeutic drugs, mostly angiotensin I converting enzym

229 Our findings, with clinically relevant therapeutic drugs (nicotine, coumarin, chlorzoxazone, an

230 a biocompatible platform for the delivery of therapeutic drugs or diagnostics, (b) conjugation of pro

231 Therefore, the need of more effective therapeutic drugs or strategies for these two types of c

232 There are currently no approved therapeutic drugs or vaccines for the disease.

233 Given that DMF is an approved human therapeutic drug, our findings support a broader use of

234 ination of the primary sequence of a protein therapeutic drug product.

235 e as 3D tissue engineering scaffolds and for therapeutic drug-release applications.

236 nsmitter transporters, targets of abused and therapeutic drugs, require Na(+) and Cl(-) for function.

237 ed to be one of the greatest achievements in therapeutic drug research having transformed HIV infecti

238 al that P450 ERAD disruption could influence therapeutic drug response and/or toxicity, warranting se

239 toxic changes reflecting the transition from therapeutic drug responses to toxic reactions at the cel

240 we reveal how beta-cyclodextrin, a potential therapeutic drug, reverts these changes.

241 ents a promising cellular tool to facilitate therapeutic drug screening for severe neurodevelopmental

242 a powerful in vivo tool for high-throughput therapeutic drug screening for the improvement of muscle

243 Cell culture assays for therapeutic drug screening today are fully automated.

244 targeting PTP1B and its analogs could be the therapeutic drug-seeds.

245 rotocells can be loaded with combinations of therapeutic (drugs, small interfering RNA and toxins) an

246 as drug metabolism (approximately 85-90% of therapeutic drugs), steroid biosynthesis, and bioactive

247 very from such injury may reveal targets for therapeutic drug strategies for promoting recovery from

248 estimate the potential savings of generic or therapeutic drug substitutions and price negotiation.

249 Savings from generic or therapeutic drug substitutions were estimated for brand

250 Savings from generic or therapeutic drug substitutions were estimated for brand

251 and targeted by approximately 60% of current therapeutic drugs such as beta-blockers, antipsychotics

252 levels in the striatum are increased by many therapeutic drugs, such as methylphenidate (MPH), which

253 It is the target of therapeutic drugs, such as methylphenidate (Ritalin), wh

254 n of the TGF-b pathway resensitizes cells to therapeutic drugs, suggesting a new combinatorial cancer

255 Therapeutic drug synergism intervened in cancer treatmen

256 suggesting this molecule as a prognostic and therapeutic drug target that could help improve the trea

257 received increasing interest as a potential therapeutic drug target with broad clinical implications

258 arget for serotonin in the human brain and a therapeutic drug target.

259 rable interest in view of its potential as a therapeutic drug target.

260 ion and psychosis, providing a potential new therapeutic drug target.

261 hence confirming the potential of SapM as a therapeutic drug target.

262 n or the development of diagnostic tools and therapeutic drugs targeting disease-causing RNAs.

263 ajor significance for the design of novel AD therapeutic drugs targeting this APP domain.

264 The investigation of V-ATPases as potential therapeutic drug targets and hence of their specific inh

265 on, establishing these proteins as potential therapeutic drug targets for trypanosomiasis.

266 nsferases involved is key to identifying new therapeutic drug targets.

267 nsferases involved is key to identifying new therapeutic drug targets.

268 ysiology and represent an important class of therapeutic drug targets.

269 e muscarinic receptor subtype family hold as therapeutic drug targets.

270 n to reveal molecular pathways and potential therapeutic drug targets.

271 their functional relevance and may offer new therapeutic drug targets.

272 ynucleinopathy pathogenesis and as potential therapeutic drug targets.SIGNIFICANCE STATEMENT Neurodeg

273 software to characterize and rank potential therapeutic (drug) targets with data from public databas

274 Therapeutic drugs that block DNA repair, including poly(

275 from two clinical trials of biomarker-guided therapeutic drugs that boosted immunity showed promising

276 The response of cancer cells to therapeutic drugs that cause DNA damage depends on genes

277 1 is an essential step in the development of therapeutic drugs that could be useful in the treatment

278 a promising molecular target for developing therapeutic drugs that exert their anticancer activities

279 s limited studies examine fibrates and other therapeutic drugs that induce cholestasis, a common find

280 This information is necessary for developing therapeutic drugs that inhibit and control amyloid forma

281 sly unknown biological targets for designing therapeutic drugs that may prevent the development of ti

282 this disorder from other conditions; and the therapeutic drugs that might selectively affect those me

283 ass spectrometry for the analysis of protein therapeutic drugs, thus providing a foundation for futur

284 The potential of the peptides to deliver a therapeutic drug to medulloblastoma cells with specifici

285 development of ISIS-APO(a)Rx as a potential therapeutic drug to reduce the risk of cardiovascular di

286 el and identifies regorafenib as a potential therapeutic drug to treat this cancer type that mimic th

287 assessment of product quality attributes for therapeutic drugs to ensure product quality.

288 hat rapid screening of mitochondria-specific therapeutic drugs to evaluate their effects on cell prot

289 ch-1-regulating flavonoid compounds as novel therapeutic drugs to regulate radiosensitivity in NSCLC

290 B has been blamed for limiting the access of therapeutic drugs to the brain, which provides a safe ha

291 be used to measure the effects of potential therapeutic drugs to treat a range of neurological disea

292 aled here may be targeted for development of therapeutic drugs to treat and prevent adenovirus-associ

293 number of small-molecule ligands, including therapeutic drugs under development and in clinical use,

294 s and animal models of narcolepsy, including therapeutic drug use and species differences.

295 otal antimicrobial use, but at the same time therapeutic drug use has increased and resistance in key

296 two reversible inhibitors, which are used as therapeutic drugs, was detectable by SPR without the nee

297 substantially increased, and preventive and therapeutic drugs will probably become available within

298 Fingolimod (FTY720) is an FDA-approved therapeutic drug with efficacy demonstrated in experimen

299 Therapeutic drugs with ototoxic side effects cause signi

300 ells are sensitive to death from exposure to therapeutic drugs with ototoxic side effects, including